Lifestyle
- Regular exercise
- Smoking cessation
- Weight management
Plasma Fibrinogen · Gerinnungsfaktor I
Fibrinogen test quantifies the concentration of fibrinogen, a glycoprotein involved in blood clot formation, in the plasma.
Reference ranges may vary slightly based on laboratory standards.
Fibrinogen, also known as Plasma Fibrinogen or Gerinnungsfaktor I, is a glycoprotein that plays a critical role in blood coagulation. It is synthesized by the liver and circulates in the plasma. Upon vascular injury, fibrinogen is converted by thrombin into fibrin, which forms a mesh that stabilizes the blood clot. Researchers have found that fibrinogen levels can reflect the body's inflammatory status, as it is an acute-phase reactant that increases in response to inflammation. Clinically, elevated fibrinogen levels are associated with an increased risk of cardiovascular diseases, such as myocardial infarction and stroke, as well as conditions like deep vein thrombosis and disseminated intravascular coagulation (DIC). Conversely, low fibrinogen levels can indicate liver disease, disseminated intravascular coagulation, or congenital fibrinogen deficiencies, which may lead to bleeding disorders. In the context of athletic performance and biohacking, fibrinogen is of interest due to its role in inflammation and clot formation. Athletes may monitor fibrinogen levels to assess recovery and inflammation status. For longevity, maintaining optimal fibrinogen levels may be beneficial in reducing cardiovascular risk. However, researchers observed that fibrinogen levels can be influenced by various factors, including acute infections, stress, and hormonal changes. Time of day and fasting status do not significantly affect fibrinogen levels, but acute physical stress or recent surgery can temporarily alter results. Therefore, it is crucial to consider these factors when interpreting fibrinogen levels.
Klinische Bedeutung
Elevated fibrinogen levels indicate increased risk of cardiovascular diseases and thrombotic events. Reduced levels suggest potential bleeding disorders or liver dysfunction.
Progressively rising fibrinogen levels suggest increasing inflammatory or thrombotic risk. Retest in 4-6 weeks if elevated.
Progressively falling fibrinogen levels may indicate resolution of inflammation or potential bleeding risk.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any new supplementation, especially if you have underlying health conditions.
Testing Frequency
Annually for adults at risk of cardiovascular disease.
Current research suggests that reference ranges for fibrinogen levels in specific populations, such as neonates and patients with dysfibrinogenemia, remain poorly defined. Researchers have not yet established optimal fibrinogen-to-albumin ratio targets for predicting outcomes in neonatal sepsis. Additionally, clinical questions remain unanswered regarding the long-term implications of fibrinogen alterations in various thrombotic and inflammatory conditions, particularly in the context of treatment efficacy and patient stratification.
616
Total Citations
12
Human/RCT
3.1
Avg. Influence
2025
Latest
This study reviewed dysfibrinogenemia, a coagulation disorder characterized by abnormal fibrinogen function. Researchers found that both inherited and acquired forms can lead to bleeding or thrombosis, and outlined laboratory tests for diagnosis.
Researchers analyzed data to assess plasma fibrinogen as a biomarker for mortality and exacerbations in COPD patients. They found that high fibrinogen levels were associated with increased risks of hospitalizations and death, suggesting its potential role in clinical trials.
This study reviewed congenital fibrinogen disorders, which can lead to bleeding issues. Researchers found that these disorders are caused by mutations in fibrinogen-encoding genes and can be classified into quantitative and qualitative deficiencies.
Researchers found that certain snake venoms can significantly reduce plasma fibrinogen levels through their proteolytic effects. The study highlights the potential use of these venoms in clinical settings for managing conditions like stroke and thrombosis, although further trials are needed to clarify their roles.
This study found that plasma fibrinogen levels increase with age, which may correlate with higher risks of cardiovascular diseases. Researchers observed that fibrinogen levels rose significantly in older adults, indicating potential underlying health processes.
Researchers summarized the laboratory testing methods for diagnosing fibrinogen disorders, which can lead to increased bleeding risk. The study discusses both acquired and congenital disorders and the importance of specialized tests.
Researchers described the coagulation process involving fibrinogen and its conversion to fibrin, which is crucial for blood clot formation. They emphasized the importance of laboratory testing for diagnosing bleeding and thrombotic disorders.
This meta-analysis assessed the prognostic value of pretreatment plasma fibrinogen levels in lung cancer patients. Researchers found that higher fibrinogen levels were significantly associated with worse overall survival and advanced disease stage.
This study established reference limits for plasma fibrinogen in healthy individuals and examined its relationship with various factors. Researchers found that fibrinogen levels increased with age and were influenced by body weight and smoking.
This study examined disseminated intravascular coagulation (DIC) in obstetrics, highlighting its association with severe maternal and perinatal outcomes. Researchers found that a combination of laboratory tests, including plasma fibrinogen levels, is necessary for diagnosis, as no single test is sufficient.
5
Total Trials
1,713
Total Enrolled
Erasmus Medical Center
150
2025
Feasibility of qLabs Fib testing in the emergency department
Sohag University
150
2024
Fibrinogen/Albumin ratio, C-reactive protein /Albumin ratio
Memorial Ankara Hospital
225
2018
Associations between polymorphic genetic variants and atrial fibrosis
Diagnostica Stago R&D
913
2016
Dynamic evolution of the number of protofibrils
Genfit
275
2012
Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis)
Research publications about Fibrinogen over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer